Harry Yoon, MD and Nabil Saba, MD, FACP, discuss recent data on novel regimens for first-line treatment of advanced/metastatic ESCC, including the immunotherapy regimen tislelizumab.
EP. 1: Trends in ESCC Incidence and Observations from Clinical PracticeDecember 21st 2022
Nabil Saba, MD, FACP and Harry Yoon, MD, briefly review the incidence of esophageal squamous cell carcinoma (ESCC), and describe how many patients present with unresectable locally advanced or metastatic disease in their clinical practice.
EP. 6: RATIONALE-306 Data on Tislelizumab in ESCCJanuary 25th 2023
Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.
EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell CancersJanuary 30th 2023
A review of other ongoing trials and emerging treatment regimens in the space and a summary of takeaways from trials on other squamous cell cancers that may also be applied to ESCC.
EP. 9: A Look Towards the Future of ESCCFebruary 6th 2023
Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.